Key facts
- Primelink Bio’s last known valuation is $40.0M (May 2024).
- It has raised $25.6M; the latest was Early Stage VC in Dec 2024.
- Notable investors include Vertex Ventures China, Fosun Health Capital, Fosun Pharma, Kaitai Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Primelink Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Primelink Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Primelink Bio
Developer of ADC biotechnology designed to develop the next generation of drug delivery systems. The company offers bioconjugation technology to synthesize a library of ADC drug candidates using a flexible and modular technology platform, and identifies the optimal ADC drug composition for the target through a screening mechanism, thereby enabling cancer patients to receive effective treatment.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2021
- Website
- primelinkbio.com/
- Ownership
- Privately Held (backing)
Primelink Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Primelink Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Primelink Bio in its N-PORT filings yet. We sweep new filings monthly.